SOURCE: INC Research

INC Research

September 28, 2010 09:01 ET

INC Research Reinforces Therapeutic Expertise With New VP Clinical Development, Endocrine

Hans-Peter Guler, MD Joins Global CRO With Leading Expertise in Endocrinology

RALEIGH, NC--(Marketwire - September 28, 2010) -  INC Research, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, has appointed Hans-Peter Guler, MD, as vice president, Clinical Development of Endocrine. Dr. Guler has more 20 years of experience in clinical research and brings a depth of leadership to the team from his years in endocrine research and expertise in areas such as metabolism, diabetes mellitus and obesity. In this role, he is responsible for providing therapeutic and clinical development oversight with internal and customer teams.

"Hans-Peter is a great addition to our stellar Endocrinology team with his unique clinical research experience across all stages of global drug development programs," said John Potthoff, COO of INC Research. "INC Research has always been therapeutically focused and has built a reputation in CNS, oncology and infectious diseases, among others. Now we are in a position to bolster therapeutic leadership in other key areas of drug development such as Endocrine. We are proud to welcome Hans-Peter to the team."

Prior to joining INC Research, Dr. Guler served as chief medical officer and VP Clinical Development at Phenomix. Prior to that, he held management positions with Regeneron Pharmaceuticals, Inc., Chiron Corp. and Ciba-Geigy Corp. His work in clinical research included studies at all stages from first-in-man to large registration trials on indications that included diabetes mellitus, obesity, rheumatoid arthritis, hepatitis C, asthma, sepsis, cardiovascular disease, and renal failure. Prior to accepting his first job in industry, he conducted some of the early studies with recombinant insulin-like growth factor I in academia. Dr. Guler is the author of more than 30 peer reviewed articles, trained in Switzerland and received his MD from the University of Zurich.

For more information on INC Research's therapeutic expertise in Endocrinology, click here.

About INC Research Inc.
INC Research is a therapeutically focused contract research organization (CRO) with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

Contact Information